OOIR: Observatory of International Research

Papers

(The H4-Index of Biodrugs is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry	301
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond	228
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy	106
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome	105
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor	86
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis	81
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis	77
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making	72
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery	61
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart	52
Acknowledgement to Referees	49
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials	45
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022	45
CAR-T Cells and the Kidney: Insights from the WHO Safety Database	41
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?	36
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies	33
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis	33
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic	33
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy	33
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells	32
Progress and Challenges in the Treatment of Fabry Disease	30
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data	30
Malaria Vaccines: Progress to Date	30
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review	30
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase	30

Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?	30
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?	28
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer	27